Celator Pharmaceuticals announced that the US Food & Drug Administration (FDA) has granted orphan drug designation to CPX-351 (Cytarabine: Daunorubicin) Liposome injection for the treatment of Acute Myeloid Leukaemia (AML).
The details can be read here.
No comments:
Post a Comment